{
    "clinical_study": {
        "@rank": "100672", 
        "arm_group": [
            {
                "arm_group_label": "rFXIII", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the effect of\n      recombinant factor XIII (rFXIII) administered to subjects with mild to moderate active\n      ulcerative colitis (UC)."
        }, 
        "brief_title": "A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Inflammation", 
            "Ulcerative Colitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Inflammation", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of ulcerative colitis for at least 3 months from the time of initial\n             diagnosis. The diagnosis must have been confirmed by historical endoscopy and\n             histology. The severity of disease must have been confirmed by endoscopy at screening\n\n          -  Currently receiving oral aminosalicylates at approved doses for at least 6 weeks of\n             at least 2g/day. Doses of oral aminosalicylates should be stable for at least two\n             weeks prior to dosing (Visit 2)\n\n        Exclusion Criteria:\n\n          -  Diagnosis of UC limited to the rectum (ulcerative proctitis only, defined as  15 cm\n             from the anal verge)\n\n          -  Requiring hospitalisation for current episode of severe UC\n\n          -  Use of biologic therapies for the treatment of UC within 12 weeks prior to dosing\n             (Visit 2)\n\n          -  Treatment failures to anti-tumour necrosis factor-alfa (anti-TNF-a) agents (e.g.\n             infliximab, adalimumab)\n\n          -  Use of immunosuppressant agents (e.g. azathioprine) within 4 weeks prior to dosing\n             (Visit 2)\n\n          -  Use of corticosteroids (oral, intravenous (i.v.), intramuscular (i.m.), or rectal )\n             within 14 days prior to dosing (Visit 2)\n\n          -  Use of enemas (corticosteroid or aminosalicylate) within 14 days prior to screening\n             (Visit 1)\n\n          -  Use of cyclosporine, tacrolimus, D-penicillamine, leflunomide, methotrexate,\n             mycophenolate mofetil, or thalidomide within 4 weeks prior to dosing (Visit 2)\n\n          -  Currently receiving total parenteral nutrition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01706159", 
            "org_study_id": "NN8717-3946", 
            "secondary_id": [
                "2011-001568-22", 
                "U1111-1120-3824"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "rFXIII", 
                "description": "rFXIII will be administered as intravenous (i.v.) injections once every second week at a dose of 35 IU/kg", 
                "intervention_name": "recombinant factor XIII", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo will be administered as intravenous (i.v.) injections once every second week at a dose of 35 IU/kg", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 7, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Rousse", 
                        "country": "Bulgaria", 
                        "zip": "7002"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zagreb", 
                        "country": "Croatia", 
                        "zip": "10000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hvidovre", 
                        "country": "Denmark", 
                        "zip": "2650"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyula", 
                        "country": "Hungary", 
                        "zip": "H5700"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lodz", 
                        "country": "Poland", 
                        "zip": "90-302"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lipetsk", 
                        "country": "Russian Federation", 
                        "zip": "398055"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knipropetrovsk", 
                        "country": "Ukraine", 
                        "zip": "49044"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Bulgaria", 
                "Croatia", 
                "Denmark", 
                "Hungary", 
                "Poland", 
                "Russian Federation", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomised, Double-blind, Placebo-controlled, Multiple-dose Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "John Francisco", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "Bulgaria: Ministry of Health", 
                "Croatia: Ministry of Health and Social Care", 
                "Denmark: Danish Medicines Agency", 
                "Hungary: Ministry of Health, Social and Family Affairs", 
                "Poland: Ministry of Health", 
                "Ukraine: Ministry of Health Ukraine", 
                "Russia: Federal Service for Control of Health Care and Social Development"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Endoscopic remission defined as a modified Baron score of 0", 
            "safety_issue": "No", 
            "time_frame": "At week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01706159"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Remission (clinical, endoscopic)", 
                "safety_issue": "No", 
                "time_frame": "At week 8"
            }, 
            {
                "measure": "Number of adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0 - 10"
            }, 
            {
                "measure": "Clearance (CL) systemically", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours after dosing"
            }, 
            {
                "measure": "Maximal concentration (Cmax) systemically", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours after dosing"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013", 
        "why_stopped": "Trial screening data did not support the medical hypothesis"
    }
}